Nirmatrelvir-ritonavir was beneficial for COVID-19 management in patients with chronic kidney disease or kidney failure, significantly reducing the risk of mortality and hospital admission. Paxlovid ® ...

Nirmatrelvir-ritonavir was beneficial for COVID-19 management in patients with chronic kidney disease or kidney failure, significantly reducing the risk of mortality and hospital admission ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. In the PAX LC trial ...

1 Nirmatrelvir/ritonavir (Paxlovid, Pfizer) is a combination protease inhibitor that prevents viral replication of SARS-CoV-2 and was authorised for emergency use in December 2021 for patients age ≥12 ...

The drug, which combines the compounds nirmatrelvir and ritonavir, entered human clinical trials in March 2021, just 12 months after its first synthesis—stunning speed for making a new bespoke drug.

Clinical trials moved quickly, and by the end of the year we had the very first oral COVID antiviral, called nirmatrelvir. The pace of the drug’s development was astonishing. Despite using the ...

Paxlovid is a prescription-only oral antiviral medication containing nirmatrelvir and ritonavir. It treats mild to moderate COVID-19 symptoms and is particularly effective if you are unvaccinated.

“A 5-day course of Paxlovid [nirmatrelvir and ritonavir] for COVID treatment is approximately $1660, but it is covered by many insurance plans, which helps with patient access,” she said.

Changes in Pregnancy-Related Mortality Associated With the Coronavirus Disease 2019 (COVID-19) Pandemic in the United States.